Tumors of the Testis — Prognostic Factors

  • G. Stoter
Part of the Ettore Majorana International Science Series book series (EMISS, volume 8)

Abstract

The determination of prognostic factors is important in any disease in order to understand the natural history and to optimize the results of therapy, i e maximal therapeutic effect in relation to minimal toxicity.

Keywords

Toxicity Lactate Tated Teratoma Bleomycin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    E. S. Newlands, R. H. J. Begent, G. J. S. Rustin, D. Parker, and K. D. Bagshaw, Further advancement in the management of malignant teratomas of the testis and other sites,The Lancet1: 948 (1983).Google Scholar
  2. 2.
    J. R. Germa-LLuch, R. H. J. Begent, and K. D. Bagshaw, Tumor-marker levels and prognosis in malignant teratoma of the testis,Br.J.Cancer, 42: 850 (1980).Google Scholar
  3. 3.
    M. J. Peckham, A. Barrett, T. J. McElwain, W. F. Hendry, and D. Raghavan, Non-seminoma germ cell tumors (malignant teratoma) of the testis,Brit.J.Urol., 53: 162 (1981).Google Scholar
  4. 4.
    M. J. Peckham, T. J. McElwain, A. Barrett, and W. F. Hendry, Combined management of malignant teratoma of the testis,The Lancet, 2: 267 (1979).Google Scholar
  5. 5.
    G. Pizzocaro, G. De Palo, A. Milani, L. Piva, S. Pilotti, F. Zanoni, and S. Monfardini, Adjuvant chemotherapy related to prognostic subgroups in stage II testicular carcinoma,Proc.Amer.Soc.Clin.Oncol., 1: 121, (1982).Google Scholar
  6. 6.
    A. Cockburn, D Vugrin, S. Hajdu, R. Mackey, M. Batata, and W. Whitmore Jr., The prognostic significance of undifferentiated (undif.) histology in seminoma,Proc.Amer.Soc.Clin.Oncol., 1: 114 (1982).Google Scholar
  7. 7.
    W. F. Whitmore Jr, D. Vugrin, and R. Golbey: Prognostic significance of choriocarcinoma elements in testis cancer,Proc.Amer.Assoc.Clin.Oncol., 1: 115 (1982).Google Scholar
  8. 8.
    M. C. Lippert and N. Javadpour, Lactic dehydrogenase in the monitoring and prognosis of testicular cancer,Cancer, 48: 2274 (1981).Google Scholar
  9. 9.
    G. Stoter, C. P. J. Vendrik, A. Struyvenberg, D. Th. Sleyer, R. Vriesendorp, H. Schraffordt Koops, A. T. van Oosterom, W. W. ten Bokkel Huinink, and H. M. Pinedo, The 5-year survival of patients with disseminated non-seminomatous testicular cancer treated with cisplatin, vinblastine, and bleomycin, Cancer, (in press).Google Scholar
  10. 10.
    . M. K. Samson, R. Fisher, R. L. Stephens, S. Rivkin, M. Opipari, T. Maloney, and C. W. Groppe, Vinblastine, Bleomycin and Cis-diamminediochloroplatinum in disseminated testicular cancer: Response to treatment and prognostic correlations,Europ.J.Cancer, 16: 1359 (1980).Google Scholar
  11. 11.
    . G. J. Bosl, N. L. Gelle, C. Cirrincione, N. J. Vogelzang, B. J. Kennedy, W. F. Whitmore, D. Vugrin, H. Scher, J. Nisselbaum, and R. B. Golbey, Multivariate analysis of prognostic variables in patients with metastatic testicular cancer,Cancer Research, 43: 3403–3407 (1983).Google Scholar
  12. 12.
    F. E. von Eyben, G. K. Jacobsen, H. Pedersen, M. Jacobsen, P. P. Clausen, P. C. Zibrandtsen, and B. Gullberg, Multivariate analysis of risk factors in patients with metastatic testicular germ cell tumors treated with vinblastine and bleomycin,Invasion Metastases, 2: 125, (1982).Google Scholar

Copyright information

© Plenum Press, New York 1985

Authors and Affiliations

  • G. Stoter
    • 1
  1. 1.Department of OncologyFree University HospitalAmsterdamThe Netherlands

Personalised recommendations